This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaski, J. C. Articles by Rosenbaum, M. B. Search for Related Content PubMed PubMed Citation Articles by Kaski, J. C. Articles by Rosenbaum, M. B.

Circulation, Vol 64, 273-279, Copyright © 1981 by American Heart Association

ARTICLES

Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone

JC Kaski, LA Girotti, H Messuti, B Rutitzky and MB Rosenbaum

Twenty-three patients with sustained, recurrent, symptomatic ventricular tachycardia were treated with oral amiodarone. Initial doses were 600-2000 mg/day and maintenance doses were 200-1200 mg/day. Amiodarone was highly effective in 20 patients (87%), seven of whom had a follow-up of 30 months or longer, including two who were followed for 5 years. Three patients died within the first 45 days, three died suddenly after a follow-up of 33.5 months, and four had a nonarrhythmic death after a follow-up of 25 months. Fifteen patients (65%) had no recurrence during a follow-up of 21.5 months, while five (22%) had isolated recurrences during a follow-up of 32.2 months. The average maintenance dose was 713 mg/day in the 15 patients who did not have recurrences and 375 mg/day in the five patients who had recurrences (p less than 0.001). Both short- and long-term tolerance were excellent and there was not a single case in which treatment had to be discontinued. The main disadvantage of amiodarone was that it took an average of 9.5 days to reach anti-arrhythmic efficacy. The main advantages were prolonged duration of action (recurrences occurred only 15-60 days after the drug was discontinued or the dose lowered, virtual absence of contraindications, doses as high as 2000 mg/day were safe and patient compliance was excellent.

This article has been cited by other articles:

				J. N. Nanas, D. A. Kontoyannis, G. P. Alexopoulos, M. I. Anastasiou-Nana, E. P. Tsagalou, S. F. Stamatelopoulos, and S. D. Moulopoulos Long-term Intermittent Dobutamine Infusion Combined With Oral Amiodarone Improves the Survival of Patients With Severe Congestive Heart Failure Chest, April 1, 2001; 119(4): 1173 - 1178. [Abstract] [Full Text] [PDF]

				S. J. Connolly Evidence-Based Analysis of Amiodarone Efficacy and Safety Circulation, November 9, 1999; 100(19): 2025 - 2034. [Full Text] [PDF]

				N. Nasir Jr., U. S. Swarna, K. A. Boahene, T. K. Doyle, and A. Pacifico Therapy of Sustained Ventricular Arrhythmias With Amiodarone: Prediction of Efficacy With Serial Electrophysiologic Studies Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 123 - 132. [Abstract] [PDF]

				R. N. FOGOROS, S. B. FIEDLER, and J. J. ELSON The Automatic Implantable Cardioverter-Defibrillator in Drug-Refractory Ventricular Tachyarrhythmias Ann Intern Med, November 1, 1987; 107(5): 635 - 641. [Abstract] [PDF]

				L. Rakita and S. M. Sobol Amiodarone in the Treatment of Refractory Ventricular Arrhythmias: Importance and Safety of Initial High-Dose Therapy JAMA, September 9, 1983; 250(10): 1293 - 1295. [Abstract] [PDF]

				F. E. MARCHLINSKI, T. S. GANSLER, H. L. WAXMAN, and M. E. JOSEPHSON Amiodarone Pulmonary Toxicity Ann Intern Med, December 1, 1982; 97(6): 839 - 845. [Abstract] [PDF]

				K. Nademanee and B. N. Singh Adverse Effects of Amiodarone-Reply JAMA, September 24, 1982; 248(12): 1448 - 1449. [Abstract] [PDF]